Race/ethnicity and HAART initiation in a military HIV infected cohort

被引:4
作者
Johnson, Erica N. [1 ,2 ]
Roediger, Mollie P. [1 ,3 ]
Landrum, Michael L. [1 ,2 ]
Crum-Cianflone, Nancy F. [1 ,4 ]
Weintrob, Amy C. [1 ,5 ]
Ganesan, Anuradha [1 ,5 ]
Okulicz, Jason F. [1 ,2 ]
Macalino, Grace E. [1 ]
Agan, Brian K. [1 ]
机构
[1] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA
[2] San Antonio Mil Med Ctr, Infect Dis Serv, San Antonio, TX USA
[3] Univ Minnesota, Biostat Div, Minneapolis, MN 55455 USA
[4] Naval Hlth Res Ctr, San Diego, CA USA
[5] Walter Reed Natl Mil Med Ctr, Infect Dis Clin, Bethesda, MD USA
来源
AIDS RESEARCH AND THERAPY | 2014年 / 11卷
基金
美国国家卫生研究院;
关键词
HIV; HAART; Race; Ethnicity; Indications for HIV treatment; Disparities in care; African Americans; ACTIVE ANTIRETROVIRAL THERAPY; EQUAL ACCESS; RACE; ADHERENCE; HIV/AIDS; PATTERNS; OUTCOMES; CARE; ASSOCIATION; PREDICTORS;
D O I
10.1186/1742-6405-11-10
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Prior studies have suggested that HAART initiation may vary by race/ethnicity. Utilizing the U.S. military healthcare system, which minimizes confounding from healthcare access, we analyzed whether timing of HAART initiation and the appropriate initiation of primary prophylaxis among those at high risk for pneumocystis pneumonia (PCP) varies by race/ethnicity. Methods: Participants in the U. S. Military HIV Natural History Study from 1998-2009 who had not initiated HAART before 1998 and who, based on DHHS guidelines, had a definite indication for HAART (CD4 <200, AIDS event or severe symptoms; Group A), an indication to consider HAART (including CD4 <350; Group B) or electively started HAART (CD4 >350; Group C) were analyzed for factors associated with HAART initiation. In a secondary analysis, participants were also evaluated for factors associated with starting primary PCP prophylaxis within four months of a CD4 count <200 cells/mm(3). Multiple logistic regression was used to compare those who started vs. delayed therapy; comparisons were expressed as odds ratios (OR). Results: 1262 participants were evaluated in the analysis of HAART initiation (A = 208, B = 637, C = 479 [ 62 participants were evaluated in both Groups A and B]; 94% male, 46% African American, 40% Caucasian). Race/ethnicity was not associated with HAART initiation in Groups A or B. In Group C, African American race/ethnicity was associated with lower odds of initiating HAART (OR 0.49, p = 0.04). Race and ethnicity were also not associated with the initiation of primary PCP prophylaxis among the 408 participants who were at risk. Conclusions: No disparities in the initiation of HAART or primary PCP prophylaxis according to race/ethnicity were seen among those with an indication for therapy. Among those electively initiating HAART at the highest CD4 cell counts, African American race/ethnicity was associated with decreased odds of starting. This suggests that free healthcare can potentially overcome some of the observed disparities in HIV care, but that unmeasured factors may contribute to differences in elective care decisions.
引用
收藏
页数:10
相关论文
共 37 条
  • [1] Anastos K, 2005, JAIDS-J ACQ IMM DEF, V39, P537
  • [2] [Anonymous], 1992, MMWR Recomm Rep, V41, P1
  • [3] [Anonymous], 2008, ANN ICRP
  • [4] Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV?
    Beach, Mary Catherine
    Keruly, Jeanne
    Moore, Richard D.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2006, 21 (06) : 661 - 665
  • [5] Bogart LM, 2000, J ACQ IMMUN DEF SYND, V23, P396
  • [6] Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort
    Brodine, SK
    Starkey, MJ
    Shaffer, RA
    Ito, SI
    Tasker, SA
    Barile, AJ
    Tamminga, CL
    Stephan, KT
    Aronson, NE
    Fraser, SL
    Wallace, MR
    Wegner, SA
    Mascola, JR
    McCutchan, FE
    [J]. AIDS, 2003, 17 (17) : 2521 - 2527
  • [7] HIV/AIDS: A minority health issue
    Cargill, VA
    Stone, VE
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2005, 89 (04) : 895 - +
  • [8] Medically eligible women who do not use HAART: The importance of abuse, drug use, and race
    Cohen, MH
    Cook, JA
    Grey, D
    Young, M
    Hanau, LH
    Tien, P
    Levine, AM
    Wilson, TE
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 2004, 94 (07) : 1147 - 1151
  • [9] Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK
    Easterbrook, P. J.
    Phillips, A. N.
    Hill, T.
    Matthias, R.
    Fisher, M.
    Gazzard, B.
    Gilson, R.
    Scullard, G.
    Johnson, M.
    Dunn, D. T.
    Orkin, C.
    Anderson, J.
    Schwenk, A.
    Leen, C.
    Sabin, C. A.
    [J]. HIV MEDICINE, 2008, 9 (01) : 47 - 56
  • [10] Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
    Emery, Sean
    Neuhaus, Jacqueline A.
    Phillips, Andrew N.
    Babiker, Abdel
    Cohen, Calvin J.
    Gatell, Jose M.
    Girard, Pierre-Marie
    Grund, Birgit
    Law, Matthew
    Losso, Marcelo H.
    Palfreeman, Adrian
    Wood, Robin
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (08): : 1133 - 1144